Vivek Subbiah/LinkedIn
Aug 4, 2025, 13:01
Vivek Subbiah: Can We at Least Make an Exception for Patients with Cancer
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared Christina Farr’s post on X:
“Completely in favor of a national medical license. Pandemic waivers worked beautifully – more access, easier care. If a full nation wide license isn’t feasible across all specialties, can we at least make an exception for patients with cancer, rare diseases and children?”
Quoting Christina Farr’s, Investor and Co-Founder at Scrub Capital post:
“Sorry but other than profit, there’s no actually good reason for state by state licensure. Especially with AI for clinical decision support. Get rid of it. Help people in rural areas get care. One national license. No brainer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 19:00
Aug 25, 2025, 17:36
Aug 25, 2025, 16:04